[The pharmacokinetics of recombinant alpha 2-interferon (reaferon)].
The use of electrochemical iodination under potentiostatic conditions resulted in generating 131I-labeled alpha 2-interferon (IF) the antiviral activity of which differed statistically insignificantly from that of the intact preparation. The resulting radioactive analogue of alpha 2-IF was successfully used for the study of pharmacokinetics of reaferon (RFN) in experimental animals which determined the parameters of the processes of its elimination from the blood stream, accumulation and release from the liver, the organ in which the highest accumulation of alpha 2-IF is observed. It is concluded from the foregoing that it would be expedient to use RFN for treatment of viral disease of the liver and the lungs.
V N
VN
Kulakov
G N
GN
Pimenova
V A
VA
Matveev
G D
GD
Kobrinskiĭ
V P
VP
Kuznetsov
D000818:Animals; D007370:Interferon Type I / Q000008:administration & dosage / Q000493:pharmacokinetics*; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007457:Iodine Radioisotopes; D008228:Lymphoma, Non-Hodgkin / Q000378:metabolism; D009368:Neoplasm Transplantation; D051381:Rats; D011994:Recombinant Proteins; D013997:Time Factors; D014018:Tissue Distribution
D007370:Interferon Type I; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D007457:Iodine Radioisotopes; D011994:Recombinant Proteins
Farmakokinetika rekombinantnogo al'fa 2-interferona (reaferona).